|
1
|
Okazaki T and Honjo T: PD-1 and PD-1
ligands: From discovery to clinical application. Int Immunol.
19:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamazaki T, Akiba H, Iwai H, Matsuda H,
Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al:
Expression of programmed death 1 ligands by murine T cells and APC.
J Immunol. 169:5538–5545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hino R, Kabashima K, Kato Y, Yagi H,
Nakamura M, Honjo T, Okazaki T and Tokura Y: Tumor cell expression
of programmed cell death-1 ligand 1 is a prognostic factor for
malignant melanoma. Cancer. 116:1757–1766. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu J, Hamrouni A, Wolowiec D, Coiteux V,
Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B: Plasma cells
from multiple myeloma patients express B7-H1 (PD-L1) and increase
expression after stimulation with IFN-{gamma} and TLR ligands via a
MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 110:296–304.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lyford-Pike S, Peng S, Young GD, Taube JM,
Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, et
al: Evidence for a role of the PD-1:PD-L1 pathway in immune
resistance of HPV-associated head and neck squamous cell carcinoma.
Cancer Res. 73:1733–1741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mittal D, Gubin MM, Schreiber RD and Smyth
MJ: New insights into cancer immunoediting and its three component
phases–elimination, equilibrium and escape. Curr Opin Immunol.
27:16–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He J, Hu Y, Hu M and Li B: Development of
PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment
for Non-Small Cell Lung Cancer. Sci Rep. 5:131102015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Noh H, Hu J, Wang X, Xia X, Satelli A and
Li S: Immune checkpoint regulator PD-L1 expression on tumor cells
by contacting CD11b positive bone marrow derived stromal cells.
Cel. Commun Signal. 13:142015. View Article : Google Scholar
|
|
12
|
Kim JM and Chen DS: Immune escape to
PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann
Oncol. 27:1492–1504. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gadiot J, Hooijkaas AI, Kaiser AD, van
Tinteren H, van Boven H and Blank C: Overall survival and PD-L1
expression in metastasized malignant melanoma. Cancer.
117:2192–2201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous von-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar
|
|
20
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: CheckMate 025 investigators: Nivolumab versus
everolimus in advanced renal-cell carcinoma. N Engl J Med.
373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen L and Flies DB: Molecular mechanisms
of T cell co-stimulation and co-inhibition. Nat Rev Immunol.
13:227–242. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang Y: Cancer immunotherapy: Harnessing
the immune system to battle cancer. J Clin Invest. 125:3335–3337.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen L and Han X: Anti-PD-1/PD-L1 therapy
of human cancer: Past, present, and future. J Clin Invest.
125:3384–3391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zou W, Wolchok JD and Chen L: PD-L1
(B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms,
response biomarkers, and combinations. Sci Transl Med.
8:328rv42016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar :
|
|
26
|
Hsieh TC and Wu JM: Resveratrol:
Biological and pharmaceutical properties as anticancer molecule.
Biofactors. 36:360–369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saud SM, Li W, Morris NL, Matter MS,
Colburn NH, Kim YS and Young MR: Resveratrol prevents tumorigenesis
in mouse model of Kras activated sporadic colorectal cancer by
suppressing oncogenic Kras expression. Carcinogenesis.
35:2778–2786. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jang M, Cai L, Udeani GO, Slowing KV,
Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta
RG, et al: Cancer chemopreventive activity of resveratrol, a
natural product derived from grapes. Science. 275:218–220. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rahman I, Biswas SK and Kirkham PA:
Regulation of inflammation and redox signaling by dietary
polyphenols. Biochem Pharmacol. 72:1439–1452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dvorakova M and Landa P: Anti-inflammatory
activity of natural stilbenoids: A review. Pharmacol Res.
124:126–145. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park EJ and Pezzuto JM: The pharmacology
of resveratrol in animals and humans. Biochim Biophys Acta.
1852:1071–1113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Britton RG, Kovoor C and Brown K: Direct
molecular targets of resveratrol: Identifying key interactions to
unlock complex mechanisms. Ann N Y Acad Sci. 1348:124–133. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Harikumar KB and Aggarwal BB: Resveratrol:
A multitargeted agent for age-associated chronic diseases. Cell
Cycle. 7:1020–1035. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tennen RI, Michishita-Kioi E and Chua KF:
Finding a target for resveratrol. Cell. 148:387–389. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zykova TA, Zhu F, Zhai X, Ma WY, Ermakova
SP, Lee KW, Bode AM and Dong Z: Resveratrol directly targets COX-2
to inhibit carcinogenesis. Mol Carcinog. 47:797–805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ito Y, Mitani T, Harada N, Isayama A,
Tanimori S, Takenaka S, Nakano Y, Inui H and Yamaji R:
Identification of carbonyl reductase 1 as a resveratrol-binding
protein by affinity chromatography using
4′-amino-3,5-dihydroxy-trans-stilbene. J Nutr Sci Vitaminol
(Tokyo). 59:358–364. 2013. View Article : Google Scholar
|
|
37
|
Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh
TC, Wu JM and Zhang Z: Crystal structure of quinone reductase 2 in
complex with resveratrol. Biochemistry. 43:11417–11426. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hsieh TC, Wang Z, Deng H and Wu JM:
Identification of glutathione sulfotransferase-pi (GSTP1) as a new
resveratrol targeting protein (RTP) and studies of
resveratrol-responsive protein changes by resveratrol affinity
chromatography. Anticancer Res. 28A:29–36. 2008.
|
|
39
|
Wang Z, Hsieh TC, Zhang Z, Ma Y and Wu JM:
Identification and purification of resveratrol targeting proteins
using immobilized resveratrol affinity chromatography. Biochem
Biophys Res Commun. 323:743–749. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Athar M, Back JH, Kopelovich L, Bickers DR
and Kim AL: Multiple molecular targets of resveratrol:
Anti-carcinogenic mechanisms. Arch Biochem Biophys. 486:95–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hsieh TC, Lin CY, Bennett DJ, Wu E and Wu
JM: Biochemical and cellular evidence demonstrating AKT-1 as a
binding partner for resveratrol targeting protein NQO2. PLoS One.
9:e1010702014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Calleri E, Pochetti G, Dossou KSS,
Laghezza A, Montanari R, Capelli D, Prada E, Loiodice F, Massolini
G, Bernier M, et al: Resveratrol and its metabolites bind to PPARs.
ChemBioChem. 15:1154–1160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang Y, Paik JH, Cho D, Cho JA and Kim CW:
Resveratrol induces the suppression of tumor-derived
CD4+CD25+ regulatory T cells. Int
Immunopharmacol. 8:542–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zou T, Yang Y, Xia F, Huang A, Gao X, Fang
D, Xiong S and Zhang J: Resveratrol inhibits CD4+ T cell
activation by enhancing the expression and activity of Sirt1. PLoS
One. 8:e751392013. View Article : Google Scholar
|
|
45
|
Craveiro M, Cretenet G, Mongellaz C,
Matias MI, Caron O, de Lima MCP, Zimmermann VS, Solary E, Dardalhon
V, Dulić V, et al: Resveratrol stimulates the metabolic
reprogramming of human CD4+ T cells to enhance effector
function. Sci Signal. 10:102017. View Article : Google Scholar
|
|
46
|
Patel KR, Scott E, Brown VA, Gescher AJ,
Steward WP and Brown K: Clinical trials of resveratrol. Ann N Y
Acad Sci. 1215:161–169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Patel KR, Brown VA, Jones DJ, Britton RG,
Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA,
et al: Clinical pharmacology of resveratrol and its metabolites in
colorectal cancer patients. Cancer Res. 70:7392–7399. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Darzynkiewicz Z, Bruno S, Del Bino G,
Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of
apoptotic cells measured by flow cytometry. Cytometry. 13:795–808.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Maier T, Güell M and Serrano L:
Correlation of mRNA and protein in complex biological samples. FEBS
Lett. 583:3966–3973. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vogel C and Marcotte EM: Insights into the
regulation of protein abundance from proteomic and transcriptomic
analyses. Nat Rev Genet. 13:227–232. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu Y, Beyer A and Aebersold R: On the
dependency of cellular protein levels on mRNA abundance. Cell.
165:535–550. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ritprajak P and Azuma M: Intrinsic and
extrinsic control of expression of the immunoregulatory molecule
PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol.
51:221–228. 2015. View Article : Google Scholar
|
|
53
|
Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI,
Park YM, Oh S, Shin JG, Yao S, Chen L, et al: Interferon regulatory
factor-1 is prerequisite to the constitutive expression and
IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett.
580:755–762. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y
and Zhang P: Interferon-γ-induced PD-L1 surface expression on human
oral squamous carcinoma via PKD2 signal pathway. Immunobiology.
217:385–393. 2012. View Article : Google Scholar
|
|
55
|
Abiko K, Matsumura N, Hamanishi J,
Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I
and Mandai M: IFN-γ from lymphocytes induces PD-L1 expression and
promotes progression of ovarian cancer. Br J Cancer. 112:1501–1509.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mandai M, Hamanishi J, Abiko K, Matsumura
N, Baba T and Konishi I: Dual faces of IFNγ in cancer progression:
A role of PD-L1 induction in the determination of pro- and
antitumor immunity. Clin Cancer Res. 22:2329–2334. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Goto K, Chiba Y and Misawa M: IL-13
induces translocation of NF-kappaB in cultured human bronchial
smooth muscle cells. Cytokine. 46:96–99. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hideshima H, Yoshida Y, Ikeda H, Hide M,
Iwasaki A, Anderson KC and Hideshima T: IKKβ inhibitor in
combination with bortezomib induces cytotoxicity in breast cancer
cells. Int J Oncol. 44:1171–1176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Burke JR, Pattoli MA, Gregor KR, Brassil
PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad
J, et al: BMS-345541 is a highly selective inhibitor of I kappa B
kinase that binds at an allosteric site of the enzyme and blocks
NF-kappa B-dependent transcription in mice. J Biol Chem.
278:1450–1456. 2003. View Article : Google Scholar
|
|
60
|
Kroesen M, Gielen P, Brok IC, Armandari I,
Hoogerbrugge PM and Adema GJ: HDAC inhibitors and immunotherapy; a
double edged sword. Oncotarget. 5:6558–6572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Woods DM, Sodré AL, Villagra A, Sarnaik A,
Sotomayor EM and Weber J: HDAC inhibition upregulates PD-1 ligands
in melanoma and augments immunotherapy with PD-1 blockade. Cancer
Immunol Res. 3:1375–1385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Howitz KT, Bitterman KJ, Cohen HY, Lamming
DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL,
et al: Small molecule activators of sirtuins extend Saccharomyces
cerevisiae lifespan. Nature. 425:191–196. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kajstura M, Halicka HD, Pryjma J and
Darzynkiewicz Z: Discontinuous fragmentation of nuclear DNA during
apoptosis revealed by discrete 'sub-G1' peaks on DNA content
histograms. Cytometry A. 71:125–131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Darzynkiewicz Z, Halicka HD and Zhao H:
Analysis of cellular DNA content by flow and laser scanning
cytometry. Adv Exp Med Biol. 676:137–147. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Akinwumi BC, Bordun KM and Anderson HD:
Biological activities of stilbenoids. Int J Mol Sci. 19:192018.
View Article : Google Scholar
|
|
66
|
Matsuoka A, Takeshita K, Furuta A, Ozaki
M, Fukuhara K and Miyata N: The 4′-hydroxy group is responsible for
the in vitro cytogenetic activity of resveratrol. Mutat Res.
521:29–35. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Semwal DK, Semwal RB, Combrinck S and
Viljoen A: Myricetin: A dietary molecule with diverse biological
activities. Nutrients. 8:902016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chen Lf, Fischle W, Verdin E and Greene
WC: Duration of nuclear NF-kappaB action regulated by reversible
acetylation. Science. 293:1653–1657. 2001. View Article : Google Scholar
|
|
69
|
Shakibaei M, Buhrmann C and Mobasheri A:
Resveratrol-mediated SIRT-1 interactions with p300 modulate
receptor activator of NF-kappaB ligand (RANKL) activation of
NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived
cells. J Biol Chem. 286:11492–11505. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zeng Z, Cheng S, Chen H, Li Q, Hu Y, Wang
Q, Zhu X and Wang J: Activation and overexpression of Sirt1
attenuates lung fibrosis via P300. Biochem Biophys Res Commun.
486:1021–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Gescher AJ and Steward WP: Relationship
between mechanisms, bioavailibility, and preclinical
chemopreventive efficacy of resveratrol: A conundrum. Cancer
Epidemiol Biomarkers Prev. 12:953–957. 2003.PubMed/NCBI
|
